Introduction {#sec1-1}
============

Hip pain, which could be the consequence of different pathologies, is reported by 19.2% \[95% confidence interval (CI) 17.9-20.6\] of people aged 65 years and older ([@ref1]-[@ref3]). The incidence of hip OA is increasing in parallel with the aging of the population and is estimated at between 47.3 (95% CI 27.8-66.8) ([@ref4]) and 88/100 000 patient-years (95% CI 65-101) ([@ref5]). Optimal management of this disease requires a combination of non-pharmacological and pharmacological modalities, thus delaying or avoiding surgical treatments (osteotomy and/or total hip prosthesis) ([@ref6]-[@ref10]). HA was initially isolated in 1934 by Karl Meyer in the vitreous humor. It is a polysaccharide macromolecule, a glycosaminoglycan of high molecular weight (MW) composed of repetitions of disaccharides of glucuronic acid and N-acetylglucosamine; it is a constituent of synovial fluid in normal joints and is synthesized by chondrocytes and synoviocytes ([@ref5]). HA has complex biological properties that could explain its analgesic effects (anti-inflammatory by inhibiting the formation and release of prostaglandin, immunomodulatory in situ), irrespective of its mechanical action on the joint fluid. The concentration of HA in an arthritic joint has been found to decrease to 50-33% of normal levels, and includes a reduction in molecular size with a consequent decrease in elasticity and viscosity of the synovial fluid ([@ref11]). In 1997 HA received Food and Drug Administration (FDA) approval in humans and it was initially used in the treatment of knee OA. This procedure should improve the physiological environment of an osteoarthritic joint by restoring its protective viscoelasticity ([@ref12]-[@ref15]), reducing friction and improving mobility ([@ref16], [@ref17]). Intra-articular hip injections have been attempted for a wide variety of hip disorders, including OA, rheumatoid arthritis ([@ref18]), acetabular labral tears, and femoral-acetabular impingement ([@ref19], [@ref20]). The injection of hyaluronic acid in the joint space allows to reach a high and durable concentration with low doses. Evidences suggest that this is the best conservative therapy for hip OA before surgery, and it can act on pain relief without modifying the morphological structure of the pathological hip and natural history of the disease. However, there is no general consensus on number and timing of hip injections and type of HA to be used. The aim of this study is to analyze the efficacy and safety of ultrasound-guided IA injection of a single dose of high-weight HA (2500 kDa) in patients affected by hip OA at a follow-up of 12 months.

Materials and Methods {#sec1-2}
=====================

This study was conducted in accordance with the principles of Declaration of Helsinki. All patients signed informed consent about the treatment they were subjected and the processing of their personal data.

Patients treated from January 2012 to December 2017 with an ultrasound-guided IA injection of high weight HA ([figure 1](#F1){ref-type="fig"}) for hip osteoarthritis were scheduled for the present study.
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Inclusion criteria were also age more than 40 years, mono- or bilateral hip OA with X-ray proof of at least partially preserved joint space (Kellgren-Lawrence stage 1-2-3) ([@ref21]), good or full joint mobility, and hip disease persisting for at least 3 months. Exclusion criteria were: the presence of severe hip OA for which it was no longer possible to recognize radiographic joint space (Kellgren-Lawrence stage 4), of inflammatory, autoimmune and septic disease and of previous hip surgeries. All patients received a single high-weight (2500 kDa) injection of 2.5% sodium hyaluronate (60 mg/4 mL).

All procedures were performed with an ultrasound guidance in accordance with the technique suggested by Migliore et al. ([@ref22]). All subjects were clinically evaluated before injection (T0) and after 3 months (T3), 6 months (T6) and 1 years (T12) utilizing the WOMAC scale and HHS.

Results were considered for statistical analysis, which was performed with JASP (software 0.7.5). At each study time, mean, standard deviation and median endpoints were calculated. For the same endpoint, comparisons were made at different study times using Student's t test for paired samples. Moreover, statistical comparisons were performed for the different groups of patients with different grade of osteoarthritis. Results were considered statistically significant for values of p\<0.05.

Results {#sec1-3}
=======

Overall, 226 subjects (135 female and 91 male) were included for the analysis of the data. The mean age was 64.2 years (SD 9.82, range 42-85) and the mean BMI was 25.8 (SD 3.66, range 18.25-32.95). Considering Kellgren-Lawrence classification 35 patients showed a Grade I of OA, 104 a Grade 2 and 87 a Grade III.

The results of WOMAC scale and HHS at T0, T3, T6 and T12 are summarized in [table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} and [graph 1](#G1){ref-type="fig"} and [2](#G2){ref-type="fig"}.

###### 

WOMAC results at T0, T3, T6 and T12

                           WOMAC_T0   WOMAC_T3   WOMAC_T6   WOMAC_T12
  ------------------------ ---------- ---------- ---------- -----------
  Valid                    74         74         74         74
  Missing                  0          0          0          0
  Mean                     62.20      52.86      48.05      50.34
  Std. Error of Mean       1.973      1.782      1.780      2.017
  Median                   65.00      52.50      45.00      47.50
  Mode                     72.00      31.00      28.00      35.00
  Std. Deviation           16.97      15.33      15.31      17.35
  Skewness                 -0.2059    0.1181     0.2398     0.3094
  Std. Error of Skewness   0.2792     0.2792     0.2792     0.2792
  Kurtosis                 -1.258     -0.8432    -0.8696    -1.003
  Std. Error of Kurtosis   0.5517     0.5517     0.5517     0.5517
  Minimum                  33.00      26.00      23.00      21.00
  Maximum                  88.00      85.00      78.00      84.00

###### 

HHS results at T0, T3, T6 and T12

                           HHS_T0    HHS_T3    HHS_T6    HHS_T12
  ------------------------ --------- --------- --------- ---------
  Valid                    74        74        74        74
  Missing                  0         0         0         0
  Mean                     57.36     70.16     75.13     72.50
  Std. Error of Mean       1.716     1.646     1.515     1.710
  Median                   62.00     73.41     80.50     77.00
  Mode                     72.00     84.00     87.00     84.00
  Std. Deviation           14.76     14.16     13.03     14.71
  Skewness                 -0.5273   -0.7459   -0.9825   -0.9874
  Std. Error of Skewness   0.2792    0.2792    0.2792    0.2792
  Kurtosis                 -0.9889   -0.4125   0.03261   0.1737
  Std. Error of Kurtosis   0.5517    0.5517    0.5517    0.5517
  Minimum                  24.80     35.20     41.65     35.20
  Maximum                  73.15     87.00     90.00     90.00

Statistical analysis showed significant improvements for WOMAC scale and HHS between results before (T0) and after HA injection (T3, T6 and T12) (p\<0.001).

No patients had adverse effects, underwent to other surgical procedures and/or need adjunctive IA injection of HA.

For each group of Kellgren-Lawrence classification a separate analysis was performed and the scores were separately calculated ([graph 3](#G3){ref-type="fig"} and [4](#G4){ref-type="fig"}). Considering the delta of change between T0 and T3 for WOMAC and Harris Hip Score, the higher was documented in patients with grade 2 of osteoarthritis.

Discussion {#sec1-4}
==========

OA can affect all the synovial joints, but knee and hip are the most frequent localizations. Although its incidence is higher in elderly, this pathology is also observed in young adults, especially in the case of intense sporting and working activities and following articular pelvic fractures ([@ref22]). It is estimated that 25-30% of the population over 45 years of age is affected by a form of OA. Hyaluronic acid plays an important role in lubrication, shock absorption and visco-elastic behaviour of synovial fluid, whose rheological properties confer the characteristic of reducing mechanical stress on the joint ([@ref23]).

At the beginning of the 90s, the Hungarian doctor Endre Alexander Balazs hypothesized that infiltrations with exogenous hyaluronic acid in patients suffering from OA could restore the visco-elasticity of the synovial fluid ([@ref11]).

The concept of viscosupplementation was subsequently developed because of the scientific evidence that the rheological properties of the synovial fluid were altered in OA and that these changes were related to the qualitative modification and quantitative decrease of hyaluronic acid ([@ref14]). It has been demonstrated that infiltrations with hyaluronic acid are effective in this pathology, thus determining the control of pain and improving joint function ([@ref20]). In addition, exogenous derivatives seem to have biological activities such as the induction of endogenous high molecular weight hyaluronic acid synthesis, interaction with pain receptors and inhibition of pro-inflammatory mediators ([@ref11]). Lùrati et al. ([@ref25]) studied the effects of HA viscosupplementation on peripheral T cells in knee and hip OA and they showed that HA injection results in a decrease in proinflammatory T cells concentrations. In particular, HA can reduce synovial inflammation and restore the rheological properties of synovial fluid.
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The significant results obtained in the infiltrative treatment of other degenerative joint diseases, such as knee OA ([@ref24]), have led the scientific community to identify new reliable therapeutic patterns also for symptomatic osteoarthritis of the hip. Even if hip viscosupplementation is certainly characterized by a greater technical difficulty than the knee one, given the deep anatomical position of the joint and the presence of the femoral vascular-nervous bundle that require the preferential use of an ultrasound guide, results for hip viscosupplementation are usually encouraging. Dallari et al. ([@ref26]) compared Platelet Rich Plasma (PRP) injections to HA or their association (PRP1HA) at 6 and 12 months follow-up. All intra-articular injections lead to a significant clinical and functional improvement, with no significant differences between the three methods of treatment. Battaglia et al. ([@ref27]) combined HA and PRP injections following a specific protocol for moderate to severe hip OA (4 injections), and they performed VAS and radiological evaluation after 1, 3, 6 and 12 months. The results showed that in 93.7% of cases there was a significant reduction of subjective pain (VAS scores) but consumption of NSAIDs was greater in patients who received the combined therapy. Migliore et al. ([@ref22]) compared HA injections to mepivacaine at 6 months follow-up (2 injections): patients in the HA group exhibited a significantly reduced Lequesne's algofunctional index and VAS at 3 and 6 months after treatment when compared with the local anesthetic group. Conrozier et al. ([@ref28]) assessed the clinical response of patients presenting with symptomatic hip osteoarthritis to the first intra-articular HA injection at 3 months of follow-up (up to four injections according to symptoms). Clinical response was defined as a 50% reduction from baseline in the Lequesne index one month after treatment. The response rate was 50% after the first injection and about half of the patients experienced significant pain relief during the 3 months following a single injection, and some of the patients who did not respond to the first injection received significant benefit from a second one.
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On the opposite, other results are not so well interpretable. Richette et al. ([@ref29]) performed a single injection of HA or placebo. VAS and WOMAC were evaluated after 3 months and compared to baseline. The results showed that there was no significant difference in terms of efficacy after one injection of HA compared with placebo in patients with hip osteoarthritis. Furthermore, an ideal hyaluronic acid derivative, by molecular weight, density and duration of action, has not yet been identified.

Some Authors compared the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip OA.

Tikiz et al. ([@ref30]) performed three hip injections (one injection per week), and evaluated VAS scale, WOMAC and Lequesne index after 1, 3 and 6 months. Both types of visco-supplementation produced a significant clinical improvement during the 6-month follow-up period, with no significant difference between higher and lower molecular weight hyaluronic acid. Atchia et al. ([@ref31]) reported no significant improvement in pain and function after a single high molecular weight HA injection in low grade hip OA when compared to standard care with no injections or to saline or non animal stabilized HA. This suggests that high molecular weight hyaluronic acids may not have a role to play in low grade hip osteoarthritis.

The results of this study suggest that the use of a preparation with high molecular weight hyaluronic acid allows to obtain satisfactory improvements in pain and joint function with a single infiltration ([@ref32]).

No patients had adverse effects, underwent to other surgical procedures and/or needs adjunctive IA injection of HA, thus demonstrating the validity and durability of the treatment over follow-up time.

However, several other therapeutic schemes are described which suggest the use of low or medium molecular weight hyaluronic acid, with a higher frequency of infiltrative sessions. The results, in relation to different situations, are contrasting and not entirely appreciable ([@ref33]).

As reported by the literature, in patients assessed with grade 1 Kellgren-Lawrence OA, the overall improvement twelve months after the infiltration is lower than that measured for grades 2 and 3 ([@ref34],[@ref35]).

This study has several limitations which includes the low number of participants, the absence of a control group, the absence of a blinded methodology, the low duration of follow-up. However, this report proved the efficacy of ultrasound guided high weight IA HA injection for hip osteoarthritic treatment.
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Conclusions {#sec1-5}
===========

Authors can affirm that a single ultrasound-guided viscosupplementation with high weight IA HA injection could be a possibility in the symptomatic treatment of hip osteoarthritis. Subjects with a moderate grade of osteoarthritis seem to represent the group that could report the maximum benefits from the procedure.
